Dr Agarwala to Present at ASCO
St. Luke’s Melanoma Expert Dr. Sanjiv Agarwala to Present at ASCO
The largest national cancer meeting, held in Chicago on June 4
Oral presentation to be recognized with “The Best of ASCO” award
Bethlehem, PA (5/25/2011) – An international group of oncology professionals come together June 4 through 8, 2011 for the American Society of Clinical Oncology (ASCO) annual meeting in Chicago to learn about the latest research in cancer care and gain practical knowledge in the fight against the disease that can be brought home to patients. Sanjiv S. Agarwala, MD, Chief of Medical Oncology and Hematology for St. Luke's Hospital & Health Network and a member of the St. Luke’s Cancer Center, is part of a select group of cancer professionals selected to give an oral presentation at the conference.
Dr. Agarwala’s talk is entitled “Randomized Phase III trial of High-Dose Interferon Alfa-2b (HDI) for 4 Weeks Induction Only in Patients with Intermediate- and High-Risk Melanoma (Intergroup trial E1697).” Dr. Agarwala served as study chair for the trial. His presentation is just one of only eight oral presentations selected out of several hundred submitted by cancer investigators worldwide and is being recognized with “The Best of ASCO” award.
“It’s a tremendous honor to not only present this abstract, but to share important information among peers – information that has the potential to impact patients,” says Dr. Agarwala. “My presentation is based on an international randomized trial involving almost 1,200 patients from the United States, Canada and Australia. The trial showed that one month of adjuvant therapy with interferon is not sufficient; patients need to receive a longer duration of one year or more of therapy to benefit.”